Thomas E. Hutson, DO, PharmD

The expert panel concludes with insights on the treatment of patients with renal cell carcinoma who progress following adjuvant therapy.

Experts on renal cell carcinoma discuss how clinical trial data inform treatment decisions, highlighting the negative results from PROSPER, CheckMate 914 Part A, and IMmotion010.

Dr Pal discusses the study design and results of the KEYNOTE-564 trial, and Benjamin Gerendash, MSN, RN, AGACNP-BC, discusses the management of adverse events associated with pembrolizumab.

The panel gives an overview of adjuvant immunotherapy options for patients with renal cell carcinoma.

Sumanta Kumar Pal, MD, FASCO, presents the case of a 48-year-old man with renal cell carcinoma, and Rana R. McKay, MD, discusses how she discusses risk of recurrence with patients.

Following a review of the LITESPARK-005 trial, experts on renal cell carcinoma discuss the potential role of belzutifan in the treatment algorithm.

The panel discusses the lenvatinib plus everolimus regimen for patients with advanced renal cell carcinoma, highlighting clinical trial data on its efficacy and safety profile.

Sumanta Kumar Pal, MD, FASCO, reviews data from the TIVO-3 study investigating tivozanib in patients with advanced renal cell carcinoma, and the panel offers its impressions on the results.

Focusing on VEGF TKIs available for the treatment of patients with metastatic renal cell carcinoma, the panel discusses the goals of therapy in the third-line setting.

Sumanta Kumar Pal, MD, FASCO, presents the case of a 66-year-old man with metastatic renal cell carcinoma, and the panel provides comprehensive insights on treatment decisions, highlighting the NCCN Guidelines.

A panel of 4 experts on renal cell carcinoma introduce themselves and discuss IMDC risk stratification criteria and the evolution of the treatment landscape.

Thomas Hutson, MD, PharmD, discusses management strategies when confronting adverse events using combination therapies in treating patients with renal cell carcinoma.

Toni Choueiri, MD, closes with promising new studies that will impact metastatic clear-cell renal cell carcinoma therapeutics in the years to come.

Both nivolumab + ipilimumab and lenvatinib + pembrolizumab TKI/IO combinations are discussed, with patient selection and appropriate use being the focus.

Dosing strategies to achieve strong efficacy and ameliorate adverse events with the combination of lenvatinib + pembrolizumab in metastatic clear-cell renal cell carcinoma.

Hutson and Choueiri compare the safety profiles of lenvatinib + pembrolizumab against other TKI/IO combinations for patients with metastatic clear-cell renal cell carcinoma.

Thomas Hutson, DO, PharmD, and Toni Choueiri, MD, talk about the phase 3 CLEAR trial at length, including each of the 3 arms of the trial and key data.

Hutson and Choueiri elaborate on the FDA-approved TKI + ICI combinations and their data from the following trials: KEYNOTE-146, JAVELIN Renal 101, and CheckMate-9ER.

Toni Choueiri, MD, focuses on combining VEGF-tyrosine kinase inhibitors with immune checkpoint inhibitors in metastatic clear-cell renal cell carcinoma.

Thomas Hutson, DO, PharmD, and Toni Choueiri, MD, discuss the available biomarkers, predictive biomarkers, and clinical predictors that are currently used in metastatic clear-cell renal cell carcinoma, as well as risk status.

The panelists discuss frontline treatment for renal cell carcinoma, highlighting TKIs targeting VEGFR and the mechanisms of action for currently approved therapeutics.

A panel discusses the role of TKI combination therapies for patients with advanced renal cell carcinoma and how they have changed the treatment landscape.

Thomas E. Hutson, DO, PharmD, medical oncologist, Texas Oncology–Baylor Charles A. Sammons Cancer Center, discusses the rationale behind the ATLAS Study, a randomized double-blind phase III study of adjuvant axitinib versus placebo in subjects at high risk of recurrent renal cell carcinoma (RCC).

Thomas E. Hutson, DO, PharmD, medical oncologist, Texas Oncology–Baylor Charles A. Sammons Cancer Center, discusses a phase I study of BPX-201 vaccine plus AP1903 for chemotherapy-naïve mCRPC.